Dulaglutide (LY2189265)

Regulatory Notice - Dulaglutide (Trulicity®): Dulaglutide is an FDA-approved prescription drug marketed as Trulicity® by Eli Lilly. Research-grade dulaglutide powder supplied by RCDbio is a research reagent only. It is not a pharmaceutical drug formulation, does not constitute a clinical alternative to Trulicity®, and is not approved for any use. RCDbio does not sell pharmaceutical Trulicity®.

Available SKUs - 2 Vial Sizes: Dulaglutide 5mg per vial · Dulaglutide 10 mg per vial. Identical compound (~63 kDa IgG4-Fc fusion protein), same mechanism, same purity (≥98%). Differentiated by vial mass only to serve different research volume requirements. See the Research Applications section for SKU selection guidance.

What is Dulaglutide (LY2189265)?

Dulaglutide (LY2189265, CAS 923950-08-7) is a biosynthetic GLP-1 receptor agonist fusion protein produced via mammalian cell expression. Each monomer of the disulfide-bonded homodimer consists of a modified GLP-1(7–37) analogue sequence carrying two key amino acid substitutions - Gly8 (conferring resistance to DPP-4 cleavage at the primary Ala8-Glu9 inactivation site) and Glu22 (enhancing receptor binding stability) - fused via a small four-amino-acid peptide linker to a modified human IgG4 heavy chain Fc fragment. The resulting disulfide-bonded homodimeric structure is approximately 63 kDa, placing it above the renal glomerular filtration threshold and within the range for FcRn-mediated endosomal recycling. These two architectural features - subthreshold renal clearance and FcRn recycling - cooperate to extend plasma half-life to approximately 80–90 hours in published pharmacokinetic models (Glaesner et al. 2010, PMID 20503261), enabling once-weekly dosing in investigational protocols. Dulaglutide is FDA-approved as Trulicity® (Eli Lilly) for once-weekly subcutaneous injection in type 2 diabetes. RCDbio supplies research-grade dulaglutide powder as a laboratory research reagent only - not as a pharmaceutical drug product.

This product is not approved by the U.S. FDA for any use without a prescription. It is not a dietary supplement or consumer product. Availability is restricted to qualified researchers and licensed laboratory institutions. Note: semaglutide is a separate compound from dulaglutide - both are GLP-1R agonists but differ in molecular architecture, receptor binding kinetics, and pharmacokinetic profiles. IRB guidance is required for clinical research. IACUC compliance is required for preclinical animal research.

Chemical Properties

Shared Properties - Both Vial Sizes

SKU Format Details

How Does Dulaglutide Work?

GLP-1R Engagement → Gs-Coupled Incretin Signalling Cascade: Investigated in GLP-1R-expressing cell model systems, dulaglutide is observed to activate the GLP-1 receptor (GLP-1R), a Class B secretin-family GPCR, through a two-stage binding process. The GLP-1 analogue portion of each monomer first contacts the receptor's extracellular N-terminal domain via electrostatic and hydrophobic complementarity interactions, creating a receptor-docked intermediate. The N-terminal alpha-helix of the GLP-1 analogue then inserts into the receptor's transmembrane bundle, completing the high-affinity complex and inducing a conformational change that activates the intracellular Gsα subunit. Gsα dissociation stimulates adenylyl cyclase → cAMP accumulation → PKA activation. In pancreatic β-cell model systems, downstream PKA activity phosphorylates KATP channel SUR1 regulatory subunits and L-type voltage-gated calcium channel proteins, driving glucose-dependent insulin granule exocytosis. The Gly8 substitution removes the DPP-4 recognition site at the Ala8-Glu9 bond, maintaining receptor engagement capability in the presence of DPP-4 in serum-containing assay media - a critical stability advantage over native GLP-1 in cell culture-based pharmacology research.

IgG4-Fc Fusion Architecture → Pharmacokinetic Engineering Research Tool: The IgG4-Fc component of dulaglutide serves multiple mechanistic functions characterized in published preclinical and clinical pharmacokinetic data (Glaesner et al. 2010, PMID 20503261; Barrington et al. 2011, PMID 21210908). Molecular weight elevation to ~63 kDa reduces renal glomerular filtration below the ~60 kDa threshold, substantially extending circulating residence time relative to small-peptide GLP-1R agonists. FcRn (neonatal Fc receptor) engagement in acidic endosomal compartments triggers transcytotic recycling of internalized dulaglutide back to the cell surface, rescuing a fraction of receptor-internalized compound from lysosomal degradation. Together, these mechanisms extend half-life to approximately 80–90 hours. In the context of in vitro receptor research, this extended half-life means that dulaglutide provides prolonged GLP-1R occupancy in biological systems without repeated compound addition - relevant for longitudinal receptor desensitisation and resensitisation studies where maintaining consistent receptor occupancy over multi-day periods is a study design requirement.

5mg vs 10mg - Research Scale Architecture: The two vial sizes represent different research programme scales without any mechanistic or pharmacological distinction. The 5mg vial is calibrated for standard GLP-1R pharmacology assays at typical laboratory volumes - supporting cAMP accumulation, β-arrestin recruitment, and radioligand displacement characterization. The 10mg vial enables comprehensive concentration-response characterisation across 10+ points, multi-arm parallel experimental designs where multiple cell lines or co-treatment conditions are compared simultaneously from a single matched lot, and extended longitudinal receptor biology studies where higher per-session reagent consumption is required.

What are the Potential Research Applications of Dulaglutide?

5mg Vial - Standard GLP-1R Pharmacology Research

• GLP-1R competitive binding characterisation: Radioligand displacement assays ([125I]-GLP-1 or [125I]-exendin-4) in GLP-1R-transfected HEK-293 or native MIN6 cell lines, characterising dulaglutide binding affinity and competitive displacement kinetics at standard assay-volume concentration points (4–6 per run)
• Gs/cAMP signalling dose-response: HTRF or AlphaScreen cAMP accumulation assays in GLP-1R-expressing βTC-6, MIN6, or INS-1 cells from picomolar to nanomolar dulaglutide concentrations, probing Gs-coupling efficiency and EC50 within the standard assay format
• GLP-1R internalisation and trafficking kinetics: Confocal fluorescence microscopy or ELISA-based surface receptor quantification in GLP-1R-GFP fusion cells following dulaglutide stimulation, investigating ligand-induced receptor internalisation and resensitisation kinetics in comparison with shorter-acting GLP-1R reference agonists
• Fc-fusion protein pharmacokinetics reference standard: Dulaglutide as a characterised Fc-GLP-1 reference compound for FcRn binding affinity studies (SPR, BLI), pharmacokinetic modelling of Fc-mediated half-life extension, and comparison against albumin-binding or PEGylation half-life extension strategies

10mg Vial - Extended and Large-Scale Research

• Comprehensive dose-response pharmacology: Full sigmoidal concentration-response curve construction across 10+ points from femtomolar to micromolar in cAMP accumulation, β-arrestin recruitment (PathHunter or NanoBRET), and receptor binding assays within a single matched-batch research programme - enabling robust EC50, Hill coefficient, and Emax characterization
• Multi-arm parallel study designs: Simultaneous independent experimental arms across multiple cell lines, agonist co-treatment conditions, or observation timepoints from a single matched lot, eliminating between-lot variability as a confound in comparative GLP-1R agonist pharmacology research
• Longitudinal GLP-1R desensitisation research: Extended experiments (2–4 weeks) investigating receptor downregulation, β-arrestin-mediated desensitisation kinetics, and receptor resensitisation following dulaglutide washout in GLP-1R-expressing cell systems - where the extended half-life architecture of the Fc-fusion is itself a research variable relative to shorter-acting GLP-1R agonists
• Comparative GLP-1R agonist pharmacology panels: Head-to-head dulaglutide vs semaglutide vs liraglutide vs exenatide receptor binding affinity, cAMP potency, and β-arrestin bias profiling studies requiring matched-batch material across all agonist concentration series simultaneously

What are the Potential Side Effects of Dulaglutide?

• GLP-1R activation in biological research systems may modulate insulin secretion, glucagon suppression, and gastric motility pathways; researchers must account for these as off-target pathway interactions in all experimental design controls, particularly in studies where glucose metabolism, gastrointestinal motility, or appetite-related endpoints are being measured
• No controlled toxicological data have been established for research-grade dulaglutide powder at either vial concentration. Individual compound investigational clinical data document gastrointestinal pathway signals (nausea, gastric motility perturbation) as the primary pharmacodynamic adverse signal class for GLP-1R agonists in clinical settings; these same receptor-mediated signals apply as off-target considerations in biological research model systems
• No human safety data has been established for this research reagent formulation at either the 5mg or 10mg vial concentration. This compound is an FDA-approved prescription drug outside its research reagent context - any non-laboratory use or distribution of research-grade dulaglutide may violate applicable federal regulations
• Data remains limited, and findings are not consistent across all preclinical model systems. No chronic toxicity profile has been established for research-grade dulaglutide powder

Risk & Handling

Handling Precautions

• Trained laboratory personnel only in a controlled laboratory environment
• PPE: nitrile gloves, laboratory coat, and eye protection required at minimum
• Reconstitute under aseptic conditions with bacteriostatic water; handle as a biologically active research protein
• The 10mg vial carries elevated handling caution requirements relative to the 5mg vial due to higher per-vial protein mass

Exposure Risks

• Risk Tier: CRITICAL/HIGHEST - Dulaglutide is an FDA-approved GLP-1R agonist (Trulicity®). Research-grade powder is not a pharmaceutical formulation. GLP-1R activation in biological systems carries insulin secretion, appetite circuit, and gastrointestinal motility pathway activation upon unintended exposure. No human safety data has been established for this research reagent. No chronic toxicity data exists at either vial concentration. Any non-research use or unauthorized distribution may violate applicable federal law. Purchaser assumes full liability for lawful use

Storage

• Store both lyophilized vials (5mg and 10mg) at −20°C in sealed, light-protected containers
• Reconstitute with bacteriostatic water under aseptic conditions; do not refreeze the reconstituted solution
• Stable ≥24 months, lyophilized under recommended storage conditions

FAQs

What research applications distinguish the 5mg from the 10mg vial?

The 5mg vial is appropriate for standard GLP-1R pharmacology assays: cAMP dose-response (4–6 concentration points), competitive radioligand binding, receptor internalisation, and Fc-fusion pharmacokinetic reference work at standard laboratory assay volumes. The 10mg vial is designed for research programmes requiring higher total reagent volume: full 10+ point dose-response curves, multi-arm parallel designs across multiple cell lines or co-treatment conditions from a single matched lot, extended longitudinal receptor desensitisation studies, and comparative GLP-1R agonist panels where multiple agonist series are run simultaneously.

How does dulaglutide differ from semaglutide as a GLP-1R research tool?

Both are long-acting GLP-1R agonists but differ in molecular architecture and half-life extension strategy. Dulaglutide is an IgG4-Fc homodimer (~63 kDa) using FcRn-mediated recycling for half-life extension (~80–90 hours). Semaglutide is a C18 fatty-diacid/OEG-modified 31-AA peptide (~4113.6 Da) using albumin binding for half-life extension (~160 hours). For research designs where Fc-receptor biology, molecular weight effects, or IgG4 effector function are study variables, dulaglutide is the appropriate GLP-1R agonist. For designs where albumin binding kinetics or smaller molecular weight peptide pharmacokinetics are the variable, semaglutide is appropriate.

Why is the Gly8 substitution important for cell culture-based GLP-1R research?

DPP-4 (dipeptidyl peptidase-4), present in serum-containing cell culture media, cleaves native GLP-1 at the Ala8-Glu9 bond within minutes, inactivating the GLP-1R agonist and complicating accurate EC50 determination and receptor occupancy modelling. Dulaglutide's Gly8 substitution blocks this cleavage site, maintaining DPP-4 resistance in serum-containing assay media and providing a substantially more stable GLP-1R agonist reference tool than native GLP-1 for cell culture-based pharmacology experiments.

What storage conditions are required for both vial formats?

Store both 5mg and 10mg lyophilized vials at −20°C in sealed, light-protected containers. Reconstitute with bacteriostatic water under aseptic conditions immediately before use. Do not re-freeze reconstituted solution. Both formats are stable for ≥24 months when lyophilized under recommended conditions.

Is the half-life (~80–90 hours) relevant to in vitro cell-based assay design?

The plasma half-life of 80–90 hours applies in physiological conditions with albumin and FcRn-expressing endosomal compartments. In standard cell-based assay media, the precise plasma pharmacokinetic half-life does not directly apply. However, the Gly8 DPP-4 resistance does apply in serum-containing media - and the FcRn recycling mechanism may also contribute to extended receptor occupancy in cell lines expressing FcRn. Researchers comparing dulaglutide to native GLP-1 in serum-containing systems should account for differential DPP-4 stability as a variable in receptor activation kinetics experiments.

References

• Glaesner W, Vick AM, Millican R, et al. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes/Metabolism Research and Reviews. 2010;26(4):287–296. https://pubmed.ncbi.nlm.nih.gov/20503261/
• Barrington P, Chien JY, Showalter HD, et al. A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. 2011;13(5):426–433. https://pubmed.ncbi.nlm.nih.gov/21210908/

Disclaimer: Dulaglutide (LY2189265) is exclusively for laboratory research purposes. RCDbio products are not intended to diagnose, prevent, treat, or cure any disease or medical condition.

The Food and Drug Administration has not evaluated the statements on our website. This product is not approved for human or veterinary use. Researchers must comply with all applicable local, state, and federal laws and regulations governing the purchase and use of research compounds. By purchasing, you agree to our Terms and Conditions. RCDbio reserves the right to refuse sales to unauthorized individuals.

ATTENTION: All RCDbio products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. They are not intended for human consumption, veterinary use, or any other non-research application. For queries, complaints, or support, contact support@rcdbio.co